Therefore, exploring the mechanisms that regulate β2-AR expression may lead to the development of methods for limiting Th1 or Th2 responsiveness to NE or β2-AR agonists that may lead to the development of CD4+T cells-mediated pathologies during chlamydia genital infection. This evidence concerns the gene CD4 and chlamydia trachomatis infectious disease.